The role of hypoxia-induced miR-210 in cancer progression

International Journal of Molecular Sciences

Volumn 16, Issue 3, 2015, Pages 6353-6372

  Dang, Kyvan ^a   Myers, Kenneth A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Angiogenesis; Apoptosis; Cancer; Hypoxia; MicroRNA; miR 210

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA 210; RNA INDUCED SILENCING COMPLEX; MICRORNA;

ANGIOGENESIS; APOPTOSIS; CANCER GENE THERAPY; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE REGULATION; CITRIC ACID CYCLE; DNA TRANSCRIPTION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GLIOMA; HUMAN; HYPOXIA; LARYNX SQUAMOUS CELL CARCINOMA; LUNG CARCINOMA; METASTASIS; MITOCHONDRIAL RESPIRATION; ONCOGENE; PROTEIN DEGRADATION; REVIEW; RNA DEGRADATION; RNA TRANSLATION; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

ANIMALS; APOPTOSIS; HUMANS; HYPOXIA; MICRORNAS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84925852915     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16036353     Document Type: Review

References (100)

1. Loboda, A.; Jozkowicz, A.; Dulak, J. HIF-1 versus HIF-2—Is one more important than the other? Vasc. Pharmacol. 2012, 56, 245–251.
2. Camps, C.; Saini, H.K.; Mole, D.R.; Choudhry, H.; Reczko, M.; Guerra-Assuncao, J.A.; Tian, Y.M.; Buffa, F.M.; Harris, A.L.; Hatzigeorgiou, A.G. et al. Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol. Cancer 2014, 13, 28.
3. Nallamshetty, S.; Chan, S.Y.; Loscalzo, J. Hypoxia: A master regulator of microRNA biogenesis and activity. Free Radic. Biol. Med. 2013, 64, 20–30.
4. Gee, H.E.; Ivan, C.; Calin, G.A.; Ivan, M. HypoxamiRs and cancer: From biology to targeted therapy. Antioxid. Redox Signal. 2014, 21, 1220–1238.
5. Melo, S.A.; Esteller, M. Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett. 2011, 585, 2087–2099.
6. Huang, X.; Le, Q.T.; Giaccia, A.J. MiR-210—Micromanager of the hypoxia pathway. Trends Mol. Med. 2010, 16, 230–237.
7. Ivan, M.; Harris, A.L.; Martelli, F.; Kulshreshtha, R. Hypoxia response and microRNAs: No longer two separate worlds. J. Cell. Mol. Med. 2008, 12, 1426–1431.
8. Hale, A.; Lee, C.; Annis, S.; Min, P.K.; Pande, R.; Creager, M.A.; Julian, C.G.; Moore, L.G.; Mitsialis, S.A.; Hwang, S.J. et al. An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim. Biophys. Acta 2014, 1843, 2528–2542.
9. Voorhoeve, P.M. MicroRNAs: Oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochim. Biophys. Acta 2010, 1805, 72–86.
10. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233.
11. Law, P.T.; Wong, N. Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2011, 26, 437–449.
12. Lei, Z.; Li, B.; Yang, Z.; Fang, H.; Zhang, G.M.; Feng, Z.H.; Huang, B. Regulation of HIF-1α and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 2009, 4, e7629.
13. Corn, P.G. Hypoxic regulation of miR-210: Shrinking targets expand HIF-1’s influence. Cancer Biol. Ther. 2008, 7, 265–267.
14. Huang, X.; Zuo, J. Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response. Acta Biochim. Biophys. Sin. 2014, 46, 220–232.
15. Fasanaro, P.; Greco, S.; Lorenzi, M.; Pescatori, M.; Brioschi, M.; Kulshreshtha, R.; Banfi, C.; Stubbs, A.; Calin, G.A.; Ivan, M. et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J. Biol. Chem. 2009, 284, 35134–35143.
16. Zhang, Z.; Sun, H.; Dai, H.; Walsh, R.M.; Imakura, M.; Schelter, J.; Burchard, J.; Dai, X.; Chang, A.N.; Diaz, R.L. et al. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 2009, 8, 2756–2768.
17. Chang, W.; Lee, C.Y.; Park, J.H.; Park, M.S.; Maeng, L.S.; Yoon, C.S.; Lee, M.Y.; Hwang, K.C.; Chung, Y.A. Survival of hypoxic human mesenchymal stem cells is enhanced by a positive feedback loop involving miR-210 and hypoxia-inducible factor 1. J. Vet. Sci. 2013, 14, 69–76.
18. Wang, J.; Zhao, J.; Shi, M.; Ding, Y.; Sun, H.; Yuan, F.; Zou, Z. Elevated expression of miR-210 predicts poor survival of cancer patients: A systematic review and meta-analysis. PLoS One 2014, 9, e89223.
19. Ying, Q.; Liang, L.; Guo, W.; Zha, R.; Tian, Q.; Huang, S.; Yao, J.; Ding, J.; Bao, M.; Ge, C. et al. Hypoxia-inducible microRNA-210 augments the metastatic potential of tumor cells by targeting vacuole membrane protein 1 in hepatocellular carcinoma. Hepatology 2011, 54, 2064–2075.
20. Hwang, H.W.; Baxter, L.L.; Loftus, S.K.; Cronin, J.C.; Trivedi, N.S.; Borate, B.; Pavan, W.J. Distinct microRNA expression signatures are associated with melanoma subtypes and are regulated by HIF1A. Pigment Cell Melanoma Res. 2014, 27, 777–787.
21. Gorospe, M.; Tominaga, K.; Wu, X.; Fahling, M.; Ivan, M. Post-transcriptional control of the hypoxic response by RNA-binding proteins and microRNAs. Front. Mol. Neurosci. 2011, 4, 7.
22. Neal, C.S.; Michael, M.Z.; Rawlings, L.H.; van der Hoek, M.B.; Gleadle, J.M. The VHL-dependent regulation of microRNAs in renal cancer. BMC Med. 2010, 8, 64.
23. Link, J.M.; Hurlin, P.J. MYC needs MNT. Cell Cycle 2013, 12, 385–386.
24. Walker, W.; Zhou, Z.Q.; Ota, S.; Wynshaw-Boris, A.; Hurlin, P.J. Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J. Cell Biol. 2005, 169, 405–413.
25. Lai, N.; Zhu, H.; Chen, Y.; Zhang, S.; Zhao, X.; Lin, Y. Differential expression of microRNA-210 in gliomas of variable cell origin and correlation between increased expression levels and disease progression in astrocytic tumours. Folia Neuropathol. 2014, 52, 79–85.
26. Nakamura, I.; Roberts, L.R. Myc, Max, and Mnt: Molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis. Gastroenterology 2011, 141, 32–34.
27. Yang, W.; Wei, J.; Guo, T.; Shen, Y.; Liu, F. Knockdown of miR-210 decreases hypoxic glioma stem cells stemness and radioresistance. Exp. Cell Res. 2014, 326, 22–35.
28. Lees, J.A.; Saito, M.; Vidal, M.; Valentine, M.; Look, T.; Harlow, E.; Dyson, N.; Helin, K. The retinoblastoma protein binds to a family of E2F transcription factors. Mol. Cell. Biol. 1993, 13, 7813–7825.
29. Masliah-Planchon, J.; Pasmant, E.; Luscan, A.; Laurendeau, I.; Ortonne, N.; Hivelin, M.; Varin, J.; Valeyrie-Allanore, L.; Dumaine, V.; Lantieri, L. et al. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: Evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics 2013, 14, 473.
30. Giannakakis, A.; Sandaltzopoulos, R.; Greshock, J.; Liang, S.; Huang, J.; Hasegawa, K.; Li, C.; O’Brien-Jenkins, A.; Katsaros, D.; Weber, B.L. et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 2008, 7, 255–264.
31. Rothe, F.; Ignatiadis, M.; Chaboteaux, C.; Haibe-Kains, B.; Kheddoumi, N.; Majjaj, S.; Badran, B.; Fayyad-Kazan, H.; Desmedt, C.; Harris, A.L. et al. Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 2011, 6, e20980.
32. Nakada, C.; Tsukamoto, Y.; Matsuura, K.; Nguyen, T.L.; Hijiya, N.; Uchida, T.; Sato, F.; Mimata, H.; Seto, M.; Moriyama, M. et al. Overexpression of miR-210, a downstream target of HIF1α, causes centrosome amplification in renal carcinoma cells. J. Pathol. 2011, 224, 280–288.
33. Crosby, M.E.; Kulshreshtha, R.; Ivan, M.; Glazer, P.M. MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res. 2009, 69, 1221–1229.
34. Tessitore, A.; Cicciarelli, G.; Del Vecchio, F.; Gaggiano, A.; Verzella, D.; Fischietti, M.; Vecchiotti, D.; Capece, D.; Zazzeroni, F.; Alesse, E. et al. MicroRNAs in the DNA damage/repair network and cancer. Int. J. Genomics 2014, 2014, doi:10.1155/2014/820248.
35. Plate, I.; Hallwyl, S.C.; Shi, I.; Krejci, L.; Muller, C.; Albertsen, L.; Sung, P.; Mortensen, U.H. Interaction with RPA is necessary for Rad52 repair center formation and for its mediator activity. J. Biol. Chem. 2008, 283, 29077–29085.
36. Feng, Z.; Scott, S.P.; Bussen, W.; Sharma, G.G.; Guo, G.; Pandita, T.K.; Powell, S.N. Rad52 inactivation is synthetically lethal with BRCA2 deficiency. Proc. Natl. Acad. Sci. USA 2011, 108, 686–691.
37. Chan, S.Y.; Loscalzo, J. MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle 2010, 9, 1072–1083.
38. Qin, Q.; Furong, W.; Baosheng, L. Multiple functions of hypoxia-regulated miR-210 in cancer. J. Exp. Clin. Cancer Res. 2014, 33, 50.
39. Devlin, C.; Greco, S.; Martelli, F.; Ivan, M. miR-210: More than a silent player in hypoxia. IUBMB Life 2011, 63, 94–100.
40. Chan, S.Y.; Zhang, Y.Y.; Hemann, C.; Mahoney, C.E.; Zweier, J.L.; Loscalzo, J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab. 2009, 10, 273–284.
41. He, M.; Lu, Y.; Xu, S.; Mao, L.; Zhang, L.; Duan, W.; Liu, C.; Pi, H.; Zhang, Y.; Zhong, M. et al. MiRNA-210 modulates a nickel-induced cellular energy metabolism shift by repressing the iron-sulfur cluster assembly proteins ISCU1/2 in Neuro-2a cells. Cell Death Dis. 2014, 5, e1090.
42. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033.
43. Puissegur, M.P.; Mazure, N.M.; Bertero, T.; Pradelli, L.; Grosso, S.; Robbe-Sermesant, K.; Maurin, T.; Lebrigand, K.; Cardinaud, B.; Hofman, V. et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ. 2011, 18, 465–478.
44. Cui, H.; Grosso, S.; Schelter, F.; Mari, B.; Kruger, A. On the pro-metastatic stress response to cancer therapies: Evidence for a positive co-operation between TIMP-1, HIF-1α, and miR-210. Front. Pharmacol. 2012, 3, 134.
45. Yang, W.; Sun, T.; Cao, J.; Liu, F.; Tian, Y.; Zhu, W. Downregulation of miR-210 expression inhibits proliferation, induces apoptosis and enhances radiosensitivity in hypoxic human hepatoma cells in vitro. Exp. Cell Res. 2012, 318, 944–954.
46. Yang, W.; Wei, J.; Sun, T.; Liu, F. Effects of knockdown of miR-210 in combination with ionizing radiation on human hepatoma xenograft in nude mice. Radiat. Oncol. 2013, 8, 102.
47. Xie, Q.; Lin, T.; Zhang, Y.; Zheng, J.; Bonanno, J.A. Molecular cloning and characterization of a human AIF-like gene with ability to induce apoptosis. J. Biol. Chem. 2005, 280, 19673–19681.
48. Kim, H.W.; Haider, H.K.; Jiang, S.; Ashraf, M. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J. Biol. Chem. 2009, 284, 33161–33168.
49. Grosso, S.; Doyen, J.; Parks, S.K.; Bertero, T.; Paye, A.; Cardinaud, B.; Gounon, P.; Lacas-Gervais, S.; Noel, A.; Pouyssegur, J. et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013, 4, e544.
50. Shang, C.; Hong, Y.; Guo, Y.; Liu, Y.H.; Xue, Y.X. MiR-210 up-regulation inhibits proliferation and induces apoptosis in glioma cells by targeting SIN3A. Med. Sci. Monit. 2014, 20, 2571–2577.
51. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006, 2, 213–219.
52. Tadokoro, H.; Umezu, T.; Ohyashiki, K.; Hirano, T.; Ohyashiki, J.H. Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells. J. Biol. Chem. 2013, 288, 34343–34351.
53. Cui, H.; Seubert, B.; Stahl, E.; Dietz, H.; Reuning, U.; Moreno-Leon, L.; Ilie, M.; Hofman, P.; Nagase, H.; Mari, B. et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene 2014, doi:10.1038/onc.2014.300.
54. Qu, A.; Du, L.; Yang, Y.; Liu, H.; Li, J.; Wang, L.; Liu, Y.; Dong, Z.; Zhang, X.; Jiang, X. et al. Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer. PLoS One 2014, 9, e90952.
55. Chen, J.; Wang, W.; Zhang, Y.; Chen, Y.; Hu, T. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med. Oncol. 2014, 31, 799.
56. Ellermeier, C.; Vang, S.; Cleveland, K.; Durand, W.; Resnick, M.B.; Brodsky, A.S. Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors. Anticancer Res. 2014, 34, 3957–3967.
57. Taddei, M.L.; Cavallini, L.; Comito, G.; Giannoni, E.; Folini, M.; Marini, A.; Gandellini, P.; Morandi, A.; Pintus, G.; Raspollini, M.R. et al. Senescent stroma promotes prostate cancer progression: The role of miR-210. Mol. Oncol. 2014, 8, 1729–1746.
58. Faraonio, R.; Salerno, P.; Passaro, F.; Sedia, C.; Iaccio, A.; Bellelli, R.; Nappi, T.C.; Comegna, M.; Romano, S.; Salvatore, G. et al. A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ. 2012, 19, 713–721.
59. Zuo, J.; Wen, M.; Lei, M.; Peng, X.; Yang, X.; Liu, Z. MiR-210 links hypoxia with cell proliferation regulation in human laryngocarcinoma cancer. J. Cell. Biochem. 2015, doi:10.1002/jcb.25059.
60. Tsuchiya, S.; Fujiwara, T.; Sato, F.; Shimada, Y.; Tanaka, E.; Sakai, Y.; Shimizu, K.; Tsujimoto, G. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J. Biol. Chem. 2011, 286, 420–428.
61. Chen, X.; Guo, J.; Xi, R.X.; Chang, Y.W.; Pan, F.Y.; Zhang, X.Z. MiR-210 expression reverses radioresistance of stem-like cells of oesophageal squamous cell carcinoma. World J. Clin. Oncol. 2014, 5, 1068–1077.
62. Andorfer, C.A.; Necela, B.M.; Thompson, E.A.; Perez, E.A. MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol. Med. 2011, 17, 313–319.
63. Brase, J.C.; Wuttig, D.; Kuner, R.; Sultmann, H. Serum microRNAs as non-invasive biomarkers for cancer. Mol. Cancer 2010, 9, 306.
64. Wittmann, J.; Jack, H.M. Serum microRNAs as powerful cancer biomarkers. Biochim. Biophys. Acta 2010, 1806, 200–207.
65. Zhao, A.; Li, G.; Peoc’h, M.; Genin, C.; Gigante, M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp. Mol. Pathol. 2013, 94, 115–120.
66. Wang, J.; Raimondo, M.; Guha, S.; Chen, J.; Diao, L.; Dong, X.; Wallace, M.B.; Killary, A.M.; Frazier, M.L.; Woodward, T.A. et al. Circulating microRNAs in pancreatic juice as candidate biomarkers of pancreatic cancer. J. Cancer 2014, 5, 696–705.
67. Barbano, R.; Palumbo, O.; Pasculli, B.; Galasso, M.; Volinia, S.; D’angelo, V.; Icolaro, N.; Coco, M.; Dimitri, L.; Graziano, P. et al. A miRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS One 2014, 9, e108950.
68. Duregon, E.; Rapa, I.; Votta, A.; Giorcelli, J.; Daffara, F.; Terzolo, M.; Scagliotti, G.V.; Volante, M.; Papotti, M. MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Hum. Pathol. 2014, 45, 1555–1562.
69. Garzon, R.; Marcucci, G.; Croce, C.M. Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9, 775–789.
70. Zhang, Y.; Wang, Z.; Gemeinhart, R.A. Progress in microRNA delivery. J. Control. Release 2013, 172, 962–974.
71. Erson, A.E.; Petty, E.M. miRNAs and cancer: New research developments and potential clinical applications. Cancer Biol. Ther. 2009, 8, 2317–2322.
72. Stenvang, J.; Petri, A.; Lindow, M.; Obad, S.; Kauppinen, S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012, 3, 1.
73. Lennox, K.A.; Owczarzy, R.; Thomas, D.M.; Walder, J.A.; Behlke, M.A. Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol. Ther. Nucleic Acids 2013, 2, e117.
74. Mattes, J.; Yang, M.; Foster, P.S. Regulation of microRNA by antagomirs: A new class of pharmacological antagonists for the specific regulation of gene function? Am. J. Respir. Cell Mol. Biol. 2007, 36, 8–12.
75. Krutzfeldt, J.; Kuwajima, S.; Braich, R.; Rajeev, K.G.; Pena, J.; Tuschl, T.; Manoharan, M.; Stoffel, M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007, 35, 2885–2892.
76. Krutzfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with “antagomirs”. Nature 2005, 438, 685–689.
77. Cho, W.C. MicroRNAs in cancer—From research to therapy. Biochim. Biophys. Acta 2010, 1805, 209–217.
78. Obad, S.; dos Santos, C.O.; Petri, A.; Heidenblad, M.; Broom, O.; Ruse, C.; Fu, C.; Lindow, M.; Stenvang, J.; Straarup, E.M. et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 2011, 43, 371–378.
79. Lanford, R.E.; Hildebrandt-Eriksen, E.S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M.E.; Kauppinen, S.; Orum, H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327, 198–201.
80. Piva, R.; Spandidos, D.A.; Gambari, R. From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment (Review). Int. J. Oncol. 2013, 43, 985–994.
81. Veldhoen, S.; Laufer, S.D.; Restle, T. Recent developments in peptide-based nucleic acid delivery. Int. J. Mol. Sci. 2008, 9, 1276–1320.
82. Bak, R.O.; Mikkelsen, J.G. miRNA sponges: Soaking up miRNAs for regulation of gene expression. Wiley Interdiscip. Rev. RNA 2014, 5, 317–333.
83. Sehgal, A.; Vaishnaw, A.; Fitzgerald, K. Liver as a target for oligonucleotide therapeutics. J. Hepatol. 2013, 59, 1354–1359.
84. Lu, C.H.; Chang, Y.H.; Lin, S.Y.; Li, K.C.; Hu, Y.C. Recent progresses in gene delivery-based bone tissue engineering. Biotechnol. Adv. 2013, 31, 1695–1706.
85. Pereira, D.M.; Rodrigues, P.M.; Borralho, P.M.; Rodrigues, C.M. Delivering the promise of miRNA cancer therapeutics. Drug Discov. Today 2013, 18, 282–289.
86. Kost, T.A.; Condreay, J.P.; Jarvis, D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat. Biotechnol. 2005, 23, 567–575.
87. Xie, J.; Burt, D.R.; Gao, G. Adeno-associated virus-mediated microRNA delivery and therapeutics. Semin. Liver Dis. 2015, 35, 81–88.
88. Park, T.G.; Jeong, J.H.; Kim, S.W. Current status of polymeric gene delivery systems. Adv. Drug Deliv. Rev. 2006, 58, 467–486.
89. Wang, H.; Jiang, Y.; Peng, H.; Chen, Y.; Zhu, P.; Huang, Y. Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Adv. Drug Deliv. Rev. 2015, 81, 142–160.
90. Trang, P.; Wiggins, J.F.; Daige, C.L.; Cho, C.; Omotola, M.; Brown, D.; Weidhaas, J.B.; Bader, A.G.; Slack, F.J. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19, 1116–1122.
91. Boussif, O.; Lezoualc’h, F.; Zanta, M.A.; Mergny, M.D.; Scherman, D.; Demeneix, B.; Behr, J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc. Natl. Acad. Sci. USA 1995, 92, 7297–7301.
92. Hwang do, W.; Son, S.; Jang, J.; Youn, H.; Lee, S.; Lee, D.; Lee, Y.S.; Jeong, J.M.; Kim, W.J.; Lee, D.S. et al. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011, 32, 4968–4975.
93. Maiorano, N.A.; Mallamaci, A. Promotion of embryonic cortico-cerebral neuronogenesis by miR-124. Neural Dev. 2009, 4, 40.
94. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8, 129–138.
95. Uchegbu, I.F. Pharmaceutical nanotechnology: Polymeric vesicles for drug and gene delivery. Expert Opin. Drug Deliv. 2006, 3, 629–640.
96. Su, J.; Baigude, H.; McCarroll, J.; Rana, T.M. Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Res. 2011, 39, e38.
97. Baigude, H.; Mc Carroll, J.; Yang, C.S.; Swain, P.M.; Rana, T.M. Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. 2007, 2, 237–241.
98. Wu, X.; Miao, L.; Yao, Y.; Wu, W.; Liu, Y.; Chen, X.; Sun, W. Electrospun fibrous scaffolds combined with nanoscale hydroxyapatite induce osteogenic differentiation of human periodontal ligament cells. Int. J. Nanomed. 2014, 9, 4135–4143.
99. Zhang, Y.; Bartz, R.; Grigoryan, G.; Bryant, M.; Aaronson, J.; Beck, S.; Innocent, N.; Klein, L.; Procopio, W.; Tucke, T. et al. Computational design and experimental characterization of peptides intended for pH-dependent membrane insertion and pore formation. ACS Chem. Biol. 2015, doi:10.1021/cb500759p.
100. Qureshi, A.T.; Doyle, A.; Chen, C.; Coulon, D.; Dasa, V.; del Piero, F.; Levi, B.; Monroe, W.T.; Gimble, J.M.; Hayes, D.J. et al. Photoactivated miR-148b-nanoparticle conjugates improve closure of critical size mouse calvarial defects. Acta Biomater. 2015, 12, 166–173.